The Medical Letter on Drugs and Therapeutics
Bunavail: Another Buprenorphine/Naloxone Formulation for Opioid Dependence
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a buccal film formulation of the partial opioid agonist buprenorphine combined with the opioid antagonist naloxone (Bunavail – BioDelivery Sciences) for maintenance treatment of opioid dependence. Sublingual tablet and film formulations of the same combination were approved earlier. The manufacturer of Bunavail claims that the new product is superior to sublingual formulations because of the convenience of buccal administration and better absorption into the blood, permitting use of lower doses.

DRUGS FOR OPIOID DEPENDENCE — Methadone was the first successful treatment for opioid addiction; it can diminish the craving for opiates without causing euphoria or sedation, but it is itself a controlled substance and can be dangerous in overdosage. Naltrexone is a long-acting oral opioid antagonist; it is effective in diminishing the euphoric effects of opioids, but it is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bunavail: Another Buprenorphine Naloxone Formulation for Opioid Dependence
Article code: 1461c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian